"Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome" . . "Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome"@en . "I, N" . . . . "RIV/00023736:_____/11:00009192" . . "7"^^ . . "11"^^ . "Neuwirtov\u00E1, R." . "Forty-eight patients with early myelodysplastic syndrome (MDS) without excess of blasts, with average initial serum ferritin levels of 2739.5 \u03BCg/L (range 825\u201311287 \u03BCg/L), were treated with deferiprone (L1) in a daily dose of 40\u201390 mg/kg. Median duration of chelation treatment was 10.9 months (range 4\u201324 months). Chelation was effective (maintained or decreased iron stores) in 16 out of 22 patients (73%) with serum ferritin levels <2000 \u03BCg/L in contrast to only 12 out of 26 patients with serum ferritin levels >2000 \u03BCg/L. Combination of L1 with recombinant human erythropoietin (rHuEPO) (30\u201340 kU/week) resulted in effective chelation in five additional patients with serum ferritin levels >3000 \u03BCg/L. Incidence of adverse effects was comparable to thatin thalassemic patients. A decreased number of granulocytes was observed in five (13%) patients and agranulocytosis occurred in two patients (4%). Administration of L1 in a daily dose of at least 75 mg/kg may represent an alternative approach" . "Hemoglobin" . "\u010Cerm\u00E1k, Jaroslav" . . "RIV/00023736:_____/11:00009192!RIV12-MZ0-00023736" . "\u0160i\u0161kov\u00E1, M." . "196700" . "deferiprone (L1); myelodysplastic syndrome; iron overload"@en . "1"^^ . "Jon\u00E1\u0161ov\u00E1, A." . "Walterov\u00E1, L." . "Hochov\u00E1, I." . "Vondr\u00E1kov\u00E1, J." . "Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome"@en . . "0363-0269" . . "000290797500005" . . "[EAF6F3DD075F]" . "http://dx.doi.org/10.3109/03630269.2011.578515" . . . "3" . "35" . . "Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome" . . . "10.3109/03630269.2011.578515" . "Forty-eight patients with early myelodysplastic syndrome (MDS) without excess of blasts, with average initial serum ferritin levels of 2739.5 \u03BCg/L (range 825\u201311287 \u03BCg/L), were treated with deferiprone (L1) in a daily dose of 40\u201390 mg/kg. Median duration of chelation treatment was 10.9 months (range 4\u201324 months). Chelation was effective (maintained or decreased iron stores) in 16 out of 22 patients (73%) with serum ferritin levels <2000 \u03BCg/L in contrast to only 12 out of 26 patients with serum ferritin levels >2000 \u03BCg/L. Combination of L1 with recombinant human erythropoietin (rHuEPO) (30\u201340 kU/week) resulted in effective chelation in five additional patients with serum ferritin levels >3000 \u03BCg/L. Incidence of adverse effects was comparable to thatin thalassemic patients. A decreased number of granulocytes was observed in five (13%) patients and agranulocytosis occurred in two patients (4%). Administration of L1 in a daily dose of at least 75 mg/kg may represent an alternative approach"@en . "US - Spojen\u00E9 st\u00E1ty americk\u00E9" . .